Search results for " Antibodies"

showing 10 items of 383 documents

High Proportions of People With Nonceliac Wheat Sensitivity Have Autoimmune Disease or Antinuclear Antibodies.

2015

BACKGROUND & AIMS: There is much interest in wheat sensitivity among people without celiac disease (CD), but little is known about any risks associated with the condition. We evaluated the prevalence of autoimmune diseases (ADs) among patients with nonceliac wheat sensitivity (NCWS), and investigated whether they carry antinuclear antibodies (ANA). METHODS: We performed a retrospective study of 131 patients diagnosed with NCWS (121 female; mean age, 29.1 years) at 2 hospitals in Italy from January 2001 through June 2011. Data were also collected from 151 patients with CD or irritable bowel syndrome (IBS) (controls). Patient medical records were reviewed to identify those with ADs. We al…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaAnti-nuclear antibodyNonceliac Wheat Sensitivity; Autoimmune Disease; Antinuclear Antibodies.Nonceliac Wheat SensitivityWheat HypersensitivityAutoimmune DiseaseThyroiditisAutoimmune DiseasesRisk FactorsInternal medicineHLA-DQ AntigensmedicinePrevalenceHumansProspective StudiesProspective cohort studyIrritable bowel syndromeRetrospective StudiesAutoimmune diseaseAntinuclear Antibodies.Hepatologybusiness.industryMedical recordGastroenterologyHLA-DQ2Retrospective cohort studyMiddle Agedmedicine.diseaseCeliac DiseaseHaplotypesItalyAntibodies AntinuclearImmunologyFemalebusinessBiomarkersGastroenterology
researchProduct

Epidemiology of hepatitis C virus infection in hemodialysis patients of Sicily

2008

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusBiomedical EngineeringMedicine (miscellaneous)BioengineeringHepacivirusmedicine.disease_causeBiomaterialsYoung AdultRenal DialysisEpidemiologymedicinePrevalenceHumansSicilyAgedAged 80 and overbusiness.industryGeneral MedicineHepatitis C AntibodiesHepatitis C ChronicMiddle AgedViral LoadVirologyChronic DiseaseRNA ViralFemaleKidney DiseasesHemodialysisbusiness
researchProduct

Infection with human herpes virus type 8 in an area at high prevalence for hepatitis C virus infection in southern Italy

2004

Summary.  The Campania Region is a geographical area of southern Italy characterized by high incidence rates of hepatocellular carcinoma and of classic Kaposi's sarcoma. Epidemiological investigations carried out among different population groups in this region have found high prevalence rates of both hepatitis C virus (HCV) and human herpesvirus type 8 (HHV-8). To assess co-infection rates of HCV and HHV-8, we carried out a cross-sectional seroepidemiological study prevalence in Pomigliano d'Arco, a Health District of Campania located 20 km away from Naples. The overall rate of HCV/HHV-8 co-infection was 3.1%, 3.5% among men and 2.7% among women. No difference emerged in the HCV/HHV-8 co-i…

AdultMalemedicine.medical_specialtyvirusesHepatitis C virusPopulationAntibodies Viralmedicine.disease_causeSeroepidemiologic StudiesVirologyEpidemiologyHumansMedicineeducationAgededucation.field_of_studyHigh prevalenceHepatologybusiness.industryTransmission (medicine)Human herpes virusPublic healthvirus diseasesHerpesviridae InfectionsHepatitis C AntibodiesMiddle Agedmedicine.diseaseHepatitis CVirologyCross-Sectional StudiesInfectious DiseasesItalyHepatocellular carcinomaHerpesvirus 8 HumanFemalebusinessJournal of Viral Hepatitis
researchProduct

Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy

2011

Abstract Background Hepatitis E virus (HEV) is a major cause of acute hepatitis in developing countries, whereas it is not considered a major health problem in Western World. Aims To investigate the spread of HEV and its possible role in causing acute hepatitis in Southern Italy. Methods Four hundred and thirty patients observed from April to December 2009 were studied and grouped as follows: 55 individuals with acute hepatitis (AH), 33 of whom cryptogenic; 321 individuals with chronic liver diseases (CLD), (278 Italians and 43 immigrants); 54 individuals without liver disease (control-group). Serum samples from all cases were tested for IgG anti-HEV antibodies and those positive to this te…

AdultMalemedicine.medical_specialtyvirusesmedicine.disease_causeZOONOSISHepatitisLiver diseaseCHRONIC LIVER-DISEASEYoung AdultHepatitis E virusEpidemiologymedicineHepatitis E virusHumansAcute hepatitisHepatitis AntibodiesHepatologybiologybusiness.industryLiver DiseasesGastroenterologyvirus diseasesMiddle AgedHepatitis Emedicine.diseaseSerum samplesVirologydigestive system diseasesHepatitis EImmunoglobulin MItalyImmunoglobulin GChronic Diseasebiology.proteinRNA ViralFemaleAntibodycryptogenic Acute HepatitisbusinessHepatitis E virus infectionAcute hepatitisSerological diagnosis Hepatitis E Virus Acute hepatitis ZOONOSIS CHRONIC LIVER-DISEASE cryptogenic Acute HepatitisSerological diagnosis
researchProduct

Hepatitis B vaccination of relatives of hepatitis B virus DNA positive carriers: an experience with plasma-derived vaccine.

1989

We assessed in a western population the efficacy of a plasma-derived hepatitis B vaccine in relatives of highly infectious hepatitis B virus (HBV) carriers. A consecutive group of 103 HbsAg, anti-HBs and anti-HBc negative household relatives of 45 HBV-DNA positive chronic carriers received a 5 micrograms dose of plasma-derived vaccine at 0, 1, 2 and 12 months. Protective levels of immunity developed in 101 subjects (97.8%) 3 months after boosting. Low responders to the vaccine were mostly found among parents and spouses of carriers, whilst offspring and siblings were usually high responders. The main discriminant in predicting a good response was age below 12 years. Hyporesponsiveness did n…

AdultViral Hepatitis VaccinesHBsAgHepatitis B vaccineEpidemiologyPopulationmedicine.disease_causeImmune systemImmunityRisk FactorsMedicineHumansHepatitis B VaccinesHepatitis B AntibodieseducationHepatitis B viruseducation.field_of_studyHepatitis B Surface Antigensbusiness.industryInfant Newbornvirus diseasesInfantHepatitis Bmedicine.diseaseHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesVaccinationImmunologyCarrier StatebusinessDNA ProbesEuropean journal of epidemiology
researchProduct

Possible link between Hashimoto's thyroiditis and oral lichen planus: a novel association found

2013

Objectives: Hashimoto's thyroiditis as well as lichen planus has been associated to a number of disorders, generally of auto-immune origin. A novel possible association between oral lichen planus (OLP) and Hashimoto's thyroiditis (HT) is here proposed on the basis of a cross-sectional survey. Materials and methods: One hundred and five unrelated OLP patients were considered. Diagnosis of HT was based on positive serum anti-TPO, anti-Tg, TSH levels and the typical ultrasound pattern of the thyroid gland. Results: In the present survey, the prevalence of HT in the OLP group was 14. 3 % whereas the prevalence of HT-related hypothyroidism in the general population was reported to be equal to 1 …

Adultendocrine systemmedicine.medical_specialtyendocrine system diseasesPopulationThyrotropinAutoimmunityHashimoto Diseasemedicine.disease_causeAutoantigensIodide PeroxidaseGastroenterologyAsymptomaticThyroiditisAutoimmunityHashimoto's thyroiditistomatognathic systemSettore MED/28 - Malattie OdontostomatologicheIron-Binding ProteinsInternal medicinePrevalencemedicineHumansThyroid NoduleOral mucosaeducationGeneral DentistryAutoantibodieseducation.field_of_studybusiness.industryThyroidMiddle AgedCirculating thyroid antibodiesmedicine.diseaseAnti-thyroid autoantibodiesThyroxinestomatognathic diseasesCross-Sectional Studiesmedicine.anatomical_structureItalyOral lichen planuHashimoto's thyroiditis; Oral lichen planus; Autoimmunity; Circulating thyroid antibodiesTriiodothyronineFemaleOral lichen planusmedicine.symptombusinessLichen Planus OralClinical Oral Investigations
researchProduct

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

2020

Abstract Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and immunosuppression for a minimum of 30 days after stopping daily PEX. We performed a retrospective, observational analysis on the use of caplacizumab in 60 patients from 29 medical centers in Germany during acute disease management. Caplacizumab led to a rapid normalization of the platelet count (median, 3 days; mean 3.78 days). One patient died after late treatment initiation due to aTTP-associated complications. In 2 patients with…

Adultmedicine.medical_specialtyExacerbationmedicine.medical_treatmentThrombotic thrombocytopenic purpuraMedizin030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicineHumansRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpuraPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain Antibodiesmedicine.diseasePurpuraDisease PresentationCardiovascular and Metabolic Diseases030220 oncology & carcinogenesisCaplacizumabmedicine.symptombusiness
researchProduct

Responses of human birch pollen allergen-reactive T cells to chemically modified allergens (allergoids)

1998

Background Allergoids are widely used in specific immunotherapy for the treatment of IgE-mediated allergic diseases. Objective The aim of this study was to analyse whether a modification of birch pollen allergens with formaldehyde affects the availability of T-cell epitopes. Methods Efficient modification of the allergens was verified by determining IgE and IgG binding activity using ELISA inhibition tests. T-cell responses to birch pollen allergoids were analysed in polyclonal systems, using peripheral blood mononuclear cells (PBMC) of five birch pollen-allergic individuals, as well as birch pollen extract-reactive T-cell lines (TCL), established from the peripheral blood of 14 birch polle…

AllergyImmunologyBiologymedicine.diseasemedicine.disease_causeImmunoglobulin EPeripheral blood mononuclear cellEpitopeAllergoidAllergenImmune systemPolyclonal antibodiesImmunologymedicinebiology.proteinImmunology and AllergyClinical & Experimental Allergy
researchProduct

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real life clinical practice: a nationwide multicenter retrospective observ…

2018

A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 p…

Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile0301 basic medicineMaleSettore MED/16 - REUMATOLOGIAAutoinflammatory disorders0302 clinical medicineRetrospective StudieAnakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile; RheumatologyChildAntibodies MonoclonalGeneral MedicineMiddle AgedAnakinraTreatment OutcomeAutoinflammationFemaleCohort studymedicine.drugHumanAdultmedicine.medical_specialtyAdolescentLogistic ModelCanakinumabNeutropeniaAntibodies Monoclonal HumanizedAutoimmune DiseaseAutoimmune Diseases03 medical and health sciencesYoung AdultRheumatologyInternal medicineInjection site reactionmedicineHumansAnakinra Autoinflammatory disorders Canakinumab Interleukin-1 Safety profile Adolescent Adult Antibodies Monoclonal Antibodies Monoclonal Humanized Autoimmune Diseases Child Female Humans Interleukin 1 Receptor Antagonist Protein Logistic Models Male Middle Aged Retrospective Studies Treatment Outcome Young AdultAdverse effectRetrospective Studies030203 arthritis & rheumatologyAnakinrabusiness.industryRetrospective cohort studymedicine.diseaseCanakinumabInterleukin 1 Receptor Antagonist ProteinLogistic Models030104 developmental biologyAutoinflammatory disorderSafety profileObservational studybusinessInterleukin-1
researchProduct

Exploring alternative hapten tethering sites for high-affinity anti-picoxystrobin antibody generation

2011

The relevance of the linker tethering site in haptens was investigated for antibody generation and immunoassay development. Three derivatives of the strobilurin fungicide picoxystrobin were synthesized with the same functionalized spacer arm located at three different positions. Protein conjugates of those haptens were employed as immunogens, and novel polyclonal antibodies were produced and characterized. All haptens afforded highly specific antibodies, but different affinities to the free analyte were observed among the obtained antisera. Next, competitive enzyme-linked immunosorbent assays were studied in several formats, and site heterology was confirmed as an effective strategy for det…

AnalytePyridinesFungicideAntibody AffinityBiophysicsEnzyme-Linked Immunosorbent AssayBiochemistryAntibodiesmedicineStrobilurinmedia_common.cataloged_instanceEuropean unionMolecular Biologymedia_commonPolyclonal antibodyAntiserumDetection limitImmunoassayBinding SitesChromatographyMolecular Structuremedicine.diagnostic_testbiologyChemistryHapten synthesisCell BiologyStrobilurinsPesticideAcrylatesSoybean analysisPolyclonal antibodiesImmunoassaybiology.proteinELISAHaptensHaptenLinker
researchProduct